Scinai Immunotherapeutics completes strategic reorganization

Scinai Immunotherapeutics (SCNI) announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previously announced acquisition of Recipharm Israel Ltd. and related commercial collaboration with Recipharm, this reorganization represents a structural transformation of the company’s operating model, designed to enhance capital efficiency, improve operational focus and position each business to independently create and capture value. Following the company’s previously announced acquisition of Recipharm Israel Ltd. in February 2026, which included a small-molecule drug development and manufacturing site in Yavne, the acquired entity was renamed Scinai Biopharma Services Ltd. As part of a corporate reorganization designed to consolidate CDMO activities, the company transferred all CDMO-related operations, including employees, infrastructure, manufacturing facilities, customer contracts and associated business activities, into this entity, establishing Scinai Biopharma Services Ltd. as the Company’s dedicated CDMO subsidiary. Scinai Biopharma Services now operates as a fully integrated, privately held CDMO platform, wholly owned by Scinai Immunotherapeutics. The reorganization was undertaken to position each part of the business more clearly for its respective stakeholders. This structure establishes a clear separation between: Scinai Biopharma Services – a dedicated, execution-focused CDMO business, and Scinai Immunotherapeutics – a streamlined R&D organization focused on advancing innovative therapeutics.